Introduction: Triple negative breast cancer (TNBC) has been classically considered a high-risk subtype. Early TNBC is usually managed with neoadjuvant chemotherapy (NAC). Residual disease after NAC is generally considered a surrogate marker for event free survival in these patients. The aim of this study was to explore the relationship between high Ki-67 expression in residual disease after NAC and disease relapse. Material and methods: This is a retrospective study of 121 patients diagnosed with TNBC, treated with neoadjuvant chemotherapy in our institution between 2008 and 2018. Clinical features, systemic and surgical therapy and pathological response were analyzed. Ki-67 expression was performed in the post-NAC surgical specimens when a pathological complete response (pCR) was not achieved. Results were correlated with number and type of relapse, and survival. Results: Eighty-one patients (67%) achieved a pCR with a median Ki-67 expression in the residual tumor of 22.5%. Thirteen patients (10.7%) relapsed and all of them belonged to the non-pCR group. In the non-relapse group, the median Ki-67 in the residual tumor was 10% compared to 40% found in the relapse group. (P=0.025). Median Ki-67 post NAC was 70% in those patients who developed a central nervous disease (CNS) relapse, 40% if was a nodal or bone recurrence and 28% if it was a visceral relapse. CNS recurrence was significantly associated with higher Ki-67 levels post NAC (P=0.010). Conclusions: Our results suggest that high expression levels of Ki-67 post-NAC could define different patterns of relapse in TNBC patients treated with NAC.
| Published in | Journal of Gynecology and Obstetrics (Volume 9, Issue 5) |
| DOI | 10.11648/j.jgo.20210905.11 |
| Page(s) | 139-144 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Triple Negative Breast Cancer, Ki-67, Neoadjuvant Chemotherapy, Relapse, Central Nervous System
| [1] | Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010; 28 (16): 2784-95. |
| [2] | Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018; 36 (20): 2105-22. |
| [3] | Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000; 406 (6797): 747-52. |
| [4] | Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010; 363 (20): 1938-48. |
| [5] | Vagia E, Mahalingam D, Cristofanilli M. The Landscape of Targeted Therapies in TNBC. Cancers (Basel). 2020; 12 (4). |
| [6] | Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013; 14 (6): 461-71. |
| [7] | Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM, et al. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat. 2010; 124 (1): 133-40. |
| [8] | Bagegni NA, Tao Y, Ademuyiwa FO. Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database. PLoS One. 2019; 14 (9): e0222358. |
| [9] | Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015; 33 (1): 13-21. |
| [10] | von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014; 15 (7): 747-56. |
| [11] | Loibl S, O'Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018; 19 (4): 497-509. |
| [12] | Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014; 384 (9938): 164-72. |
| [13] | Fayanju OM, Ren Y, Thomas SM, Greenup RA, Plichta JK, Rosenberger LH, et al. The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT): A Review of 20,000 Breast Cancer Patients in the National Cancer Data Base (NCDB). Ann Surg. 2018; 268 (4): 591-601. |
| [14] | McAndrew N, DeMichele A. Neoadjuvant Chemotherapy Considerations in Triple-Negative Breast Cancer. J Target Ther Cancer. 2018; 7 (1): 52-69. |
| [15] | Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst. 2011; 103 (22): 1656-64. |
| [16] | Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991; 19 (5): 403-10. |
| [17] | Phillips T, Murray G, Wakamiya K, Askaa J, Huang D, Welcher R, et al. Development of standard estrogen and progesterone receptor immunohistochemical assays for selection of patients for antihormonal therapy. Appl Immunohistochem Mol Morphol. 2007; 15 (3): 325-31. |
| [18] | Hernández-Cortés G, Fuertes S, Martinez V, Rubio M et al. MRI guided ROLL/SNOLL in breast cancer patients treated with neoadjuvant chemotherapy. Rev Esp Med Nucl Imagen Mol. 2020. doi.org/10.1016/j.remn.2020.09.001. |
| [19] | Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003; 12 (5): 320-7. |
| [20] | Van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001; 19 (22): 4224-37. |
| [21] | Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001 (30): 96-102. |
| [22] | Gagliato DeM, Gonzalez-Angulo AM, Lei X, Theriault RL, Giordano SH, Valero V, et al. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol. 2014; 32 (8): 735-44. |
| [23] | Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med. 2017; 376 (22): 2147-59. |
| [24] | Wu Q, Ma G, Deng Y, Luo W, Zhao Y, Li W, et al. Prognostic Value of Ki-67 in Patients With Resected Triple-Negative Breast Cancer: A Meta-Analysis. Front Oncol. 2019; 9: 1068. |
| [25] | Matsubara N, Mukai H, Masumoto M, Sasaki M, Naito Y, Fujii S, et al. Survival outcome and reduction rate of Ki-67 between pre- and post-neoadjuvant chemotherapy in breast cancer patients with non-pCR. Breast Cancer Res Treat. 2014; 147 (1): 95-102. |
| [26] | Matsubara N, Mukai H, Fujii S, Wada N. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer. Breast Cancer Res Treat. 2013; 137 (1): 203-12. |
| [27] | Chen Ch, Zhang Y, Huang Z, Wu J, Huang W, Zhang G. Decrease in the Ki-67 index during neoadjuvant chemotherapy predicts favorable relapse-free survival in patients with locally advanced breast cancer. Cancer Biol Med. 2019. doi: 10.20892/j.issn.2095-3941.2018.0423. |
| [28] | Zhu X, Chen L, Huang B, Wang Y, Ji L, Wu J, Di G, Liu G, Yu K, Shao Z, Wang Z. The prognostic and predictive potential of Ki-67 in triple negative breast cancer. Scientific Reports. 2020. 10: 225. doi: 10.1038/s41598-019-57094-3. |
APA Style
Gines Hernandez-Cortes, Javier Hornedo, Raquel Murillo, Ricardo Sainz De La Cuesta, Lucia Gonzalez-Cortijo. (2021). Patterns of Relapse Related to High Expression of Ki-67 After Neoadjuvant Chemotherapy in Triple Negative Breast Cancer. Journal of Gynecology and Obstetrics, 9(5), 139-144. https://doi.org/10.11648/j.jgo.20210905.11
ACS Style
Gines Hernandez-Cortes; Javier Hornedo; Raquel Murillo; Ricardo Sainz De La Cuesta; Lucia Gonzalez-Cortijo. Patterns of Relapse Related to High Expression of Ki-67 After Neoadjuvant Chemotherapy in Triple Negative Breast Cancer. J. Gynecol. Obstet. 2021, 9(5), 139-144. doi: 10.11648/j.jgo.20210905.11
AMA Style
Gines Hernandez-Cortes, Javier Hornedo, Raquel Murillo, Ricardo Sainz De La Cuesta, Lucia Gonzalez-Cortijo. Patterns of Relapse Related to High Expression of Ki-67 After Neoadjuvant Chemotherapy in Triple Negative Breast Cancer. J Gynecol Obstet. 2021;9(5):139-144. doi: 10.11648/j.jgo.20210905.11
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.jgo.20210905.11,
author = {Gines Hernandez-Cortes and Javier Hornedo and Raquel Murillo and Ricardo Sainz De La Cuesta and Lucia Gonzalez-Cortijo},
title = {Patterns of Relapse Related to High Expression of Ki-67 After Neoadjuvant Chemotherapy in Triple Negative Breast Cancer},
journal = {Journal of Gynecology and Obstetrics},
volume = {9},
number = {5},
pages = {139-144},
doi = {10.11648/j.jgo.20210905.11},
url = {https://doi.org/10.11648/j.jgo.20210905.11},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jgo.20210905.11},
abstract = {Introduction: Triple negative breast cancer (TNBC) has been classically considered a high-risk subtype. Early TNBC is usually managed with neoadjuvant chemotherapy (NAC). Residual disease after NAC is generally considered a surrogate marker for event free survival in these patients. The aim of this study was to explore the relationship between high Ki-67 expression in residual disease after NAC and disease relapse. Material and methods: This is a retrospective study of 121 patients diagnosed with TNBC, treated with neoadjuvant chemotherapy in our institution between 2008 and 2018. Clinical features, systemic and surgical therapy and pathological response were analyzed. Ki-67 expression was performed in the post-NAC surgical specimens when a pathological complete response (pCR) was not achieved. Results were correlated with number and type of relapse, and survival. Results: Eighty-one patients (67%) achieved a pCR with a median Ki-67 expression in the residual tumor of 22.5%. Thirteen patients (10.7%) relapsed and all of them belonged to the non-pCR group. In the non-relapse group, the median Ki-67 in the residual tumor was 10% compared to 40% found in the relapse group. (P=0.025). Median Ki-67 post NAC was 70% in those patients who developed a central nervous disease (CNS) relapse, 40% if was a nodal or bone recurrence and 28% if it was a visceral relapse. CNS recurrence was significantly associated with higher Ki-67 levels post NAC (P=0.010). Conclusions: Our results suggest that high expression levels of Ki-67 post-NAC could define different patterns of relapse in TNBC patients treated with NAC.},
year = {2021}
}
TY - JOUR T1 - Patterns of Relapse Related to High Expression of Ki-67 After Neoadjuvant Chemotherapy in Triple Negative Breast Cancer AU - Gines Hernandez-Cortes AU - Javier Hornedo AU - Raquel Murillo AU - Ricardo Sainz De La Cuesta AU - Lucia Gonzalez-Cortijo Y1 - 2021/09/04 PY - 2021 N1 - https://doi.org/10.11648/j.jgo.20210905.11 DO - 10.11648/j.jgo.20210905.11 T2 - Journal of Gynecology and Obstetrics JF - Journal of Gynecology and Obstetrics JO - Journal of Gynecology and Obstetrics SP - 139 EP - 144 PB - Science Publishing Group SN - 2376-7820 UR - https://doi.org/10.11648/j.jgo.20210905.11 AB - Introduction: Triple negative breast cancer (TNBC) has been classically considered a high-risk subtype. Early TNBC is usually managed with neoadjuvant chemotherapy (NAC). Residual disease after NAC is generally considered a surrogate marker for event free survival in these patients. The aim of this study was to explore the relationship between high Ki-67 expression in residual disease after NAC and disease relapse. Material and methods: This is a retrospective study of 121 patients diagnosed with TNBC, treated with neoadjuvant chemotherapy in our institution between 2008 and 2018. Clinical features, systemic and surgical therapy and pathological response were analyzed. Ki-67 expression was performed in the post-NAC surgical specimens when a pathological complete response (pCR) was not achieved. Results were correlated with number and type of relapse, and survival. Results: Eighty-one patients (67%) achieved a pCR with a median Ki-67 expression in the residual tumor of 22.5%. Thirteen patients (10.7%) relapsed and all of them belonged to the non-pCR group. In the non-relapse group, the median Ki-67 in the residual tumor was 10% compared to 40% found in the relapse group. (P=0.025). Median Ki-67 post NAC was 70% in those patients who developed a central nervous disease (CNS) relapse, 40% if was a nodal or bone recurrence and 28% if it was a visceral relapse. CNS recurrence was significantly associated with higher Ki-67 levels post NAC (P=0.010). Conclusions: Our results suggest that high expression levels of Ki-67 post-NAC could define different patterns of relapse in TNBC patients treated with NAC. VL - 9 IS - 5 ER -
Email: